In vivo tumor angiogenesis imaging with site-specific labeled99mTc-HYNIC-VEGF
β Scribed by Francis G. Blankenberg; Marina V. Backer; Zoia Levashova; Vimalkumar Patel; Joseph M. Backer
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 256 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The in vivo 99mTc-RBC labelling efficiency and stability of labelling was assessed after pretinning with a high-stannous content DTPA kit (Sn DTPA) in comparison with Sn-pyrophosphate (Sn PPi) and a low-stannous DTPA kit (DTPA). The distribution in Sprague Dawley rats showed that similar fractions o
Red blood cells of 10 patients were labelled with 99mTc by the in vivo method, 5 of the patients were orally administered with 400 mg potassium perchlorate at the time of stannous pyrophosphate injection and 5 ml blood was withdrawn at 10 min postinjection of pertechnetate to determine the labelling
## Abstract Bevacizumab is a humanized monoclonal antibody that binds to tumorβsecreted vascular endothelial growth factor (VEGF)βA and inhibits tumor angiogenesis. In 2004, the antibody was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic colorectal carcinoma i